Cargando…

Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry

AIMS: To assess the association between combination, dose and use of current guideline‐recommended target doses (TD) of renin–angiotensin system inhibitors (RASi), angiotensin receptor–neprilysin inhibitors (ARNi) and β‐blockers, and outcomes in a large and unselected contemporary cohort of patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	D'Amario, Domenico, Rodolico, Daniele, Rosano, Giuseppe M.C., Dahlström, Ulf, Crea, Filippo, Lund, Lars H., Savarese, Gianluigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd. 2022
Materias:	Drug Therapy in Real‐world Practice
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315143/ https://www.ncbi.nlm.nih.gov/pubmed/35257446 http://dx.doi.org/10.1002/ejhf.2477

Ejemplares similares

Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry
por: Kapelios, Chris J, et al.
Publicado: (2021)

Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry
por: Lindberg, Felix, et al.
Publicado: (2022)

Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new Chronic Kidney Disease Epidemiology Collaboration creatinine equation for estimating glomerular filtration rate
por: Butt, Jawad H., et al.
Publicado: (2022)

The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure
por: Savarese, Gianluigi, et al.
Publicado: (2019)

Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction
por: Stolfo, Davide, et al.
Publicado: (2023)

Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real‐world data from the Swedish Heart Failure Registry
por: Savarese, G., et al.
Publicado: (2020)

Medical Treatment of Heart Failure with Reduced Ejection Fraction in the Elderly
por: Milinković, Ivan, et al.
Publicado: (2022)

A registry‐based algorithm to predict ejection fraction in patients with heart failure
por: Uijl, Alicia, et al.
Publicado: (2020)

Nurse‐Led Heart Failure Clinics Are Associated With Reduced Mortality but Not Heart Failure Hospitalization
por: Savarese, Gianluigi, et al.
Publicado: (2019)

Cell Therapy in Heart Failure with Preserved Ejection Fraction
por: Frljak, Sabina, et al.
Publicado: (2022)

Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
por: D’Amario, Domenico, et al.
Publicado: (2019)

Persistent High Burden of Heart Failure Across the Ejection Fraction Spectrum in a Nationwide Setting
por: Stolfo, Davide, et al.
Publicado: (2022)

Non-cardiac comorbidities and mortality in patients with heart failure with reduced vs. preserved ejection fraction: a study using the Swedish Heart Failure Registry
por: Ergatoudes, Constantinos, et al.
Publicado: (2019)

Eligibility for the 4 Pharmacological Pillars in Heart Failure With Reduced Ejection Fraction at Discharge
por: D'Amario, Domenico, et al.
Publicado: (2023)

Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction
por: Agarwalla, Anjali, et al.
Publicado: (2022)

Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction
por: Löfström, Ulrika, et al.
Publicado: (2019)

Heart failure with mid-range or mildly reduced ejection fraction
por: Savarese, Gianluigi, et al.
Publicado: (2021)

Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
por: Gori, Mauro, et al.
Publicado: (2021)

Risk of stroke in patients with heart failure and sinus rhythm: data from the Swedish Heart Failure Registry
por: Hjalmarsson, Clara, et al.
Publicado: (2020)

Use of evidence‐based therapy in heart failure with reduced ejection fraction across age strata
por: Stolfo, Davide, et al.
Publicado: (2022)

GENERATOR HEART FAILURE DataMart: An integrated framework for heart failure research
por: D’Amario, Domenico, et al.
Publicado: (2023)

“Real World” Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry
por: Simpson, Joanne, et al.
Publicado: (2019)

Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction
por: Uijl, Alicia, et al.
Publicado: (2021)

Patient profile and outcomes associated with follow‐up in specialty vs. primary care in heart failure
por: Lindberg, Felix, et al.
Publicado: (2022)

Age differences in contemporary treatment of patients with chronic heart failure and reduced ejection fraction
por: Veenis, Jesse F, et al.
Publicado: (2019)

Telemedicine, Artificial Intelligence and Humanisation of Clinical Pathways in Heart Failure Management: Back to the Future and Beyond
por: D’Amario, Domenico, et al.
Publicado: (2020)

Endpoints in Heart Failure Drug Development
por: Hussain, Aliza, et al.
Publicado: (2022)

Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction
por: Blair, Hannah A.
Publicado: (2021)

Association between heart failure quality of care and mortality: a population‐based cohort study using nationwide registries
por: Batra, Gorav, et al.
Publicado: (2022)

A pilot clinical trial of cell therapy in heart failure with preserved ejection fraction
por: Vrtovec, Bojan, et al.
Publicado: (2022)

Epidemiology, Clinical Characteristics and Cause-specific Outcomes in Heart Failure with Preserved Ejection Fraction
por: Kapelios, Chris J, et al.
Publicado: (2023)

Corrigendum to: Digoxin use in contemporary heart failure with reduced ejection fraction: An analysis from the Swedish Heart Failure Registry
Publicado: (2023)

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials
por: Teerlink, John R., et al.
Publicado: (2020)

Clinical Characteristics of De Novo Heart Failure and Acute Decompensated Chronic Heart Failure: Are They Distinctive Phenotypes That Contribute to Different Outcomes?
por: Raffaello, Wilson Matthew, et al.
Publicado: (2021)

Cardiac resynchronization therapy with or without defibrillator in patients with heart failure
por: Schrage, Benedikt, et al.
Publicado: (2021)

Limited value of NT-proBNP as a prognostic marker of all-cause mortality in patients with heart failure with preserved and mid-range ejection fraction in primary care: A report from the swedish heart failure register
por: Eriksson, Björn, et al.
Publicado: (2019)

Heart failure induced by itraconazole
por: Okuyan, Hızır, et al.
Publicado: (2013)

Evidence-based Therapy in Older Patients with Heart Failure with Reduced Ejection Fraction
por: Stolfo, Davide, et al.
Publicado: (2022)

Dementia‐related adverse events in PARADIGM‐HF and other trials in heart failure with reduced ejection fraction
por: Cannon, Jane A., et al.
Publicado: (2016)

Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial
por: Chatur, Safia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sc3gsmf3v1ul4qbjgv0l94a3th